Multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant
to both isoniazid and rifampicin with or without resistance to other drugs is among the most …

Tuberculosis (TB) continues to be a significant problem globally. Treatment includes a
multiple drug regimen with isoniazid, rifampicin (rifampin), pyrazinamide and ethambutol …

Tuberculosis (TB) is a growing international health concern, since it is the leading infectious
cause of death in the world today. In particular, the increasing prevalence of multidrug …

Multidrug‐resistant tuberculosis (MDR‐TB) with bacillary resistance to at least isoniazid and
rifampicin in vitro is a worldwide phenomenon. Hot spots of the disease are found scattered …

Background We carried out this study to determine the efficacy and safety of a regimen
containing kanamycin, ethionamide, isoniazid, para-aminosalicylic acid (PAS) and …

The use of gatifloxacin (GAT) in combination with ethionamide (ETA) with or without
pyrazinamide (PZA) for a 12-week treatment period followed by an 8-week observation …

Tuberculosis (TB), which kills more people than any other infectious disease, was declared
a global emergency by the World Health Organization in 1993. The emergence of new …

Fluoroquinolones (FQs) are important drugs to treat drug-resistant tuberculosis. In this
review we integrated pharmacokinetic properties (PK) and microbiological susceptibility …

Tuberculosis (TB) remains an important health problem worldwide. The structure necessary
for delivering TB treatment and implementing the directly observed treatment accounts for …

OBJECTIVE: To determine the trend in changes in susceptibility of Mycobacterium
tuberculosis strains, including to second-line drugs, from patients with a history of previous …